Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Aug 2;9:687524. doi: 10.3389/fcell.2021.687524

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Chen, Sun, Dai, Li, Yan, Zhang, Xiao, Shen, Huang, Xiang, Zhang, Tan, Yang, Nie, Huang, Lian and He.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Knockdown of CRNDE sensitizes HCC cells to sorafenib in vivo. (A–C) The size, weight and photograph of xenograft tumors in the groups with or without stable knockdown of CRNDE (LV-shCRNDE or LV-NC) and administration of sorafenib (n = 5). (D) Immunohistochemical staining assay for Ki67, SQSTM1/p62 and ATG4B in the xenograft tumors of different groups as in panel (A) (scale bar: 100 μm). (E) TUNEL staining assay for apoptosis in the xenograft tumors of different groups as in panel (A) (scale bar: 20 μm). (F) Western blot analysis of cleaved PARP, SQSTM1/p62, LC3, and ATG4B in 3 xenograft samples of each group as in panel (A). (G) qPCR analysis of CRNDE and ATG4B mRNA in the xenograft tumors of different groups as in panel (A). C, control; S, sorafenib. *P < 0.05; **P < 0.01; ***P < 0.001.